Nanotechnology for Pediatric Retinoblastoma Therapy
Retinoblastoma is a rare, sometimes hereditary, pediatric cancer. In high-income countries this disease has a survival rate approaching 100%, while in low- and middle-income countries the prognosis is fatal for about 80% of cases. Depending on the stage of the disease, different therapeutic protocol...
Saved in:
Main Authors: | Eleonora Russo (Author), Andrea Spallarossa (Author), Bruno Tasso (Author), Carla Villa (Author), Chiara Brullo (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Indole Antitumor Agents in Nanotechnology Formulations: An Overview
by: Eleonora Russo, et al.
Published: (2023) -
New Pyrazolyl Thioureas Active against the <i>Staphylococcus</i> Genus
by: Anna Maria Schito, et al.
Published: (2024) -
Microbiological Screening of 5-Functionalized Pyrazoles for the Future Development of Optimized Pyrazole-Based Delivery Systems
by: Chiara Brullo, et al.
Published: (2022) -
Nanotechnology-based strategies overcoming the challenges of retinoblastoma: a comprehensive overview and future perspectives
by: Shymaa Hatem, et al.
Published: (2024) -
Retinoblastoma
by: Agnieszka Budny, et al.
Published: (2018)